Earnings call transcript: bioMérieux tops Q3 2026 revenue forecast, shares rise

bioMérieux reported Q3 revenue of $1.04 billion, $20 million above the $1.02 billion forecast, with organic sales growth of 8%; its four GO•28 growth drivers rose 13%. The company confirmed 2026 guidance of 3%–5% organic sales growth and 0%–10% CEBIT growth, while noting respiratory-demand, China and input-cost risks. Shares rose 3.93% to $93.95 in pre-market trading.

Analysis

The key distinction is between durable demand and growth that is difficult to annualize. The outbreak-related lift has ended, and management itself cautioned against extrapolating the unusually strong underlying non-respiratory quarter. Meanwhile, the respiratory season is a near-term swing factor: a weak peak could push full-year sales toward the low end of guidance and reduce operating leverage even if the installed base keeps expanding.

The more important 6–18 month test is monetization, not placements. A larger SPOTFIRE footprint creates a reagent-revenue opportunity, but utilization remains sensitive to test mix and respiratory activity; approval of new panels is not equivalent to reimbursed, recurring demand. Watch reagent growth and usage per instrument alongside net placements. Margin risk is also underappreciated: electronics and resin costs can arrive with a lag, while FX relief is not a structural offset. Cost actions may protect the broad CEBIT range, but the wide range leaves limited visibility on the earnings conversion of growth.

The premarket gain raises the bar for an immediate chase. The contrarian risk is that investors capitalize a strong quarter as a new run-rate despite management’s explicit caution and the seasonal/one-off components. Conversely, persistent broad-based non-respiratory demand and improving reagent pull-through would support the growth-quality case. QIAGEN’s ownership change is not a near-term disruption thesis on the information available; treat any competitive opportunity as unproven.

Key Decisions for Investors

• Avoid chasing the initial gap in BIM. Consider a starter long only if the shares hold near the prior €-equivalent listing-price reference of $90.40 after the open; treat a sustained break below that level as a failed reaction, not an automatic add. Reassess on Q4 respiratory trends and the February 2027 outlook.
• For the next 1–3 months, track respiratory surveillance through the late-November/December peak and compare it with management’s full-year sales range. A weak season raises downside risk to the low end; a stronger season is upside, but not evidence by itself of structural acceleration.
• Do not underwrite SPOTFIRE placements or new panel approvals as recurring revenue yet. Seek evidence in reagent growth, utilization per instrument, U.S. reimbursement/pricing for the vaginitis panel, and customer adoption; delayed reimbursement or weak pull-through would falsify the installed-base monetization thesis.
• Keep QGEN on watch rather than initiating a relative-value trade: the call supplied no evidence of near-term commercial disruption. Revisit only if customer churn, product delays, or channel changes become independently observable.